Results 1 to 10 of about 47,532 (242)

Naltrexone-Bupropion and Behavior Therapy, Alone and Combined, for Binge-Eating Disorder: Randomized Double-Blind Placebo-Controlled Trial

American Journal of Psychiatry, 2022
OBJECTIVE Binge-eating disorder, the most prevalent eating disorder, is a serious public health problem associated with obesity, psychiatric and medical comorbidities, and functional impairments.
Carlos M. Grilo, Janet A. Lydecker, Sarah K. Fineberg, Jorge O. Moreno, Valentina Ivezaj, Ralitza Gueorguieva   +5 more
openalex   +3 more sources

Efficacy and Safety of AXS-05 (Dextromethorphan-Bupropion) in Patients With Major Depressive Disorder

Journal of Clinical Psychiatry, 2022
Objective: Altered glutamatergic neurotransmission has been implicated in the pathogenesis of depression. This trial evaluated the efficacy and safety of AXS-05 (dextromethorphan-bupropion), an oral N-methyl-D-aspartate (NMDA) receptor antagonist and σ1 ...
Dan V. Iosifescu, Amanda Jones, Cedric O’Gorman, Caroline Streicher, Samantha Feliz, Maurizio Fava, Herriot Tabuteau   +6 more
openalex   +3 more sources

Is there a potential of misuse for venlafaxine and bupropion? [PDF]

Frontiers in Pharmacology, 2018
© 2018 Schifano and Chiappini. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the ...
Anderson, Augustin, Baker, Baribeau, Bolden-Watson, Campagne, Carvalho, Chiappini, Chiappini, Chouinard, Cosci, Cutler, Deluca, Evans, Fava, Fava, Fountain, Francesconi, Groot, Harvey, Harvey, Hill, Hilliard, Holland, Hopper, Hu, Kantor, Kelly, Khurshid, Kim, Koga, Kotzalidis, Langguth, Lewin, Llorca, Maj, McCormick, Muth, Nelson, Orsolini, Parker, Phillips, Quaglio, Redrobe, Reeves, Renoir, Rettew, Rudolph, Sabljić, Schifano, Schifano, Shang, Shenouda, Sir, Stahl, Stahl, Stahl, Stall, Stassinos, Taylor, Vento, Weikop, Welsh, Wilson, Yoon   +64 more
core   +4 more sources

Naltrexone/bupropion for binge‐eating disorder: A randomized, double‐blind, placebo‐controlled trial

Obesity, 2023
Binge‐eating disorder (BED) is a prevalent psychiatric disorder associated with obesity. Few evidence‐based treatments exist for BED, particularly pharmacological options. This study tested the efficacy of naltrexone/bupropion for BED.
C. Grilo, Janet A. Lydecker, Ania M. Jastreboff, Brian Pittman, Sherry A. McKee   +4 more
semanticscholar   +1 more source

Dextromethorphan-bupropion (Auvelity) for the Treatment of Major Depressive Disorder

Clinical Psychopharmacology and Neuroscience, 2023
Depression is a significant cause of morbidity and mortality globally. Although various pharmacologic options exist for depression, treatments are limited by delayed or incomplete therapeutic response, low rates of remission, and adverse effects ...
Brian McCarthy, Hannah Bunn, Morgan Santalucia, Charlotte Wilmouth, A. Muzyk, Colin M. Smith   +5 more
semanticscholar   +1 more source

Bupropion Mediated Effects on Depression, Attention Deficit Hyperactivity Disorder, and Smoking Cessation.

Health Psychology Research, 2023
Bupropion had been in use since the late 1980s as an unconventional treatment for depression. Unlike other antidepressants, bupropion has no serotonergic activity and inhibits the reuptake of norepinephrine and dopamine.
Alan L. Clark, B. Tate, Bretton Urban, R. Schroeder, Sonja A. Gennuso, Shahab Ahmadzadeh, D. McGregor, Brook Girma, Sahar Shekoohi, A. Kaye   +9 more
semanticscholar   +1 more source

Anti-obesity Medication (Naltrexon/ Bupropion) in Obesity Management: Single-Centre Early Experience. [PDF]

Malays J Med Sci
Tan SF, Mukhtar F, Ng OC, Mohd Yusof BN, Muhammadun Basar NA, Chandrabose T, Xiang Jun C, Nor Hanipah Z.   +7 more
europepmc   +2 more sources

Bupropion and Naltrexone in Methamphetamine Use Disorder.

New England Journal of Medicine, 2021
BACKGROUND The use of naltrexone plus bupropion to treat methamphetamine use disorder has not been well studied. METHODS We conducted this multisite, double-blind, two-stage, placebo-controlled trial with the use of a sequential parallel comparison ...
M. Trivedi, R. Walker, W. Ling, Adriane M. dela Cruz, G. Sharma, T. Carmody, Udi E. Ghitza, A. Wahle, Mora Kim, K. Shores‐Wilson, S. Sparenborg, P. Coffin, J. Schmitz, K. Wiest, G. Bart, S. Sonne, Sidarth Wakhlu, A. Rush, E. Nunes, S. Shoptaw   +19 more
semanticscholar   +1 more source

Pharmacovigilance Study on Adverse Events of Nicotine Replacement Therapy, Bupropion, and Varenicline in Patients with Chronic Obstructive Pulmonary Disease. [PDF]

Int J Chron Obstruct Pulmon Dis
Wang YD, Wang YT, Chen HH, Bao JK, Chen SM, Chen DX.   +5 more
europepmc   +3 more sources

GP prescribing of nicotine replacement and bupropion to aid smoking cessation in England and Wales [PDF]

, 2004
Aims Prescribing nicotine replacement therapy (NRT) or bupropion for smoking cessation is of considerable importance to public health but little is known about prescribing practices.
McEwen, A, Owen, L, West, R
core   +1 more source